Academic and Community Cancer Research United

21 total trials 6 currently recruiting 4 completed

Trial Pipeline

RECRUITING Phase 2

Retifanlimab with Bevacizumab and Hypofractionated Radiotherapy for the Treatment of Recurrent Glioblastoma

NCT06160206

RECRUITING Phase 2

Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy

NCT06238648

RECRUITING Phase 2

Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

NCT05910801

RECRUITING Phase 2

Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer

NCT05168163

RECRUITING Phase 2

Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma

NCT04626791

RECRUITING Phase 2

Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer

NCT04660760

ACTIVE NOT RECRUITING Phase 2

Regorafenib and Durvalumab for the Treatment of High-Risk Liver Cancer

NCT05194293

ACTIVE NOT RECRUITING Phase 2

Selinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk, Recurrent or Refractory Multiple Myeloma

NCT04756401

ACTIVE NOT RECRUITING Phase 2

PEA for the Relief of Chemotherapy-Induced Peripheral Neuropathy

NCT05246670

ACTIVE NOT RECRUITING Phase 2

Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer

NCT03992456

ACTIVE NOT RECRUITING Phase 2

Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer

NCT04117945

ACTIVE NOT RECRUITING Phase 1

Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer

NCT03337087

ACTIVE NOT RECRUITING Phase 2

Doxorubicin, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients With Stage I-II Hodgkin Lymphoma

NCT03233347

ACTIVE NOT RECRUITING Phase 2

Multi-epitope Folate Receptor Alpha Peptide Vaccine, GM-CSF, and Cyclophosphamide in Treating Patients With Triple Negative Breast Cancer

NCT03012100

ACTIVE NOT RECRUITING Phase 2

Pembrolizumab in Treating Patients With Small Bowel Adenocarcinoma That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery

NCT02949219

ACTIVE NOT RECRUITING Phase 1

R-ICE and Lenalidomide in Treating Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma

NCT02628405

ACTIVE NOT RECRUITING Phase 2

Nivolumab and Brentuximab Vedotin in Treating Older Patients With Untreated Hodgkin Lymphoma

NCT02758717

COMPLETED Phase 2

Capecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colorectal Cancer

NCT02873195

COMPLETED Phase 3

Apixaban or Dalteparin in Reducing Blood Clots in Patients With Cancer Related Venous Thromboembolism

NCT02585713

COMPLETED Phase 2

Pregabalin in Preventing Acute Pain Syndrome in Patients Receiving Paclitaxel

NCT01637077

COMPLETED NA

White Wine or Nutritional Supplement in Improving Appetite in Patients With Cancer

NCT00936728

What the Pipeline for Academic and Community Cancer Research United Shows

According to the ClinicalTrials.gov registry, Academic and Community Cancer Research United is linked to 21 US clinical trials across every stage of research activity. Of those, 6 studies are currently recruiting — about 29% of the sponsor's indexed portfolio — and 4 are already marked complete, representing roughly 19% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.

The phase mix for Academic and Community Cancer Research United reports 1 late-stage studies (Phase 3 and Phase 4 combined) and 19 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.

The top therapeutic focus area indexed for Academic and Community Cancer Research United is Metastatic Colorectal Carcinoma with 3 linked trials, and 9 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial